-Bloomberg The corpse of Indian farmer Bengali Singh burned to ash atop a blazing funeral pyre on the banks of the river Ganges in 2006. Five years later, the dead man was recorded as being paid by India's $33 billion rural jobs program to dig an irrigation canal in Jharkhand state. Officials in his village and the surrounding region used at least 500 identities, including those of Singh, a disabled child of...

-Live Mint CCEA clears recommendations on sugar sector made by Rangarajan panel; subsidy burden to rise Pushing ahead with long-pending reforms of the sugar industry, the cabinet on Thursday approved the dismantling of rules requiring sugar mills to sell the sweetener at below-market prices through the public distribution system (PDS) and abolished curbs on open market sale. The cabinet committee on economic affairs cleared the recommendations made by a panel headed by C....

-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...

-The Indian Express India is no insecure dictatorship junking international obligations for cheap populism. The highest court of the world's largest democracy has made a nuanced distinction between real innovation and marketing gimmickry. Yet, the Swiss pharmaceutical giant Novartis's response to the recent Supreme Court verdict in Novartis vs Union of India has been imperial in tone. The judgment "discourages innovative drug discovery", it claimed. It accused Indian law of lagging...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...